Affin Hwang Capital Research Highlights

Company Update – Alliance Bank (BUY, Maintain) Banking on Niche Markets

kltrader
Publish date: Thu, 19 Apr 2018, 09:50 AM
kltrader
0 20,423
This blog publishes research highlights from Affin Hwang Capital Research.

Banking on Niche Markets

Alliance Bank Malaysia (ABM) remains operationally strong with steadily improving NIM, stable fee income generation and a sound loanbook (as implied by a GIL ratio 1.18%, LLC at 121.9% in 9MFY18). Potential for earnings upside lies in FY19E after the completion of a transformation exercise in FY18, leading to higher sales productivity to drive operating income expansion while the cost-to-income ratio may see further improvement. Meanwhile, we do not expect a detrimental impact to its earnings with the adoption of MFRS 9 standards. Maintain BUY, PT at RM4.80 (1.3x P/BV target).

Expansion in the Portfolio of Better ‘RAR’ Loans Boost Income

Being a smallish bank, ABM’s core strategy has been to boost the higher ‘risk-adjusted return’ (RAR) loans as the group does not compete directly in the same space as the large-sized banks do. The strategy has worked well, and this has been reflected in its higher NIMs (9MFY18: +11bps) and the expansion in fund-based income (9MFY18: +5.6% yoy) despite flat loans growth as at Dec 2017. Overwhelmingly positive response to the Alliance One Account loan consolidation account (launched April17), with loan approvals of RM1.5bn ytd will be a boost to the higher RAR portfolio.

Transformation Exercise to Raise Group’s Productivity Completed

ABM undertook a transformation exercise at the start of FY18E, with initiatives targeting the SME customers, migration of consumer loan accounts, streamlining and restructuring branches, beefing up the sales workforce and on technology/marketing. Of the total cost of RM90m, RM59.5m has been spent in 9MFY18.

MFRS 9 Impact Should Not be Detrimental to Profits

Given ABM’s sound asset quality (GIL ratio 1.18%), in our view, the balance sheet adjustment for additional provisions on Day-1 (starting 1 April 2018) should not be an issue.

Reaffirm BUY Rating, PT Unchanged at RM4.80 (1.3x P/B Target)

Reaffirm BUY on ABM, with a 12-month PT of RM4.80 based on a 1.3x CY18E P/BV multiple, underpinned by a CY18E ROE of 9.7% and a 8.6% cost of equity. Though FY18E is expected to see a dip in earnings, we believe that FY19E will be a year where there will be more earnings upside due to potentially higher revenues and the absence of the one-off transformation cost. Downside risks – NIM compression, higher credit loss.

Source: Affin Hwang Research - 19 Apr 2018

Related Stocks
Market Buzz
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment